Last updated: August 1, 2026
Butoconazole nitrate is an established topical azole antifungal used primarily for vulvovaginal candidiasis. Its U.S. commercial product, Gynazole-1, is a single-dose 2% vaginal cream. Clinical development is mature, with no meaningful late-stage innovation pipeline publicly associated with the active ingredient. Market opportunity is concentrated in generic and private-label vaginal antifungal products, while regulatory, patent and commercial barriers are limited.
What is the current FDA status of butoconazole nitrate?
Butoconazole nitrate is FDA-approved as a vaginal antifungal for the local treatment of vulvovaginal candidiasis caused by susceptible Candida species.
| Product |
Active ingredient |
Dosage form |
Strength |
Administration |
Regulatory status |
| Gynazole-1 |
Butoconazole nitrate |
Vaginal cream |
2% |
Single intravaginal dose |
FDA-approved |
| Femstat |
Butoconazole nitrate |
Vaginal cream |
2% |
Multi-day regimen |
Historical product |
| Generic products |
Butoconazole nitrate |
Vaginal cream |
2% |
Primarily single-dose or equivalent vaginal use |
Abbreviated new drug application pathway |
The FDA-approved Gynazole-1 label identifies butoconazole nitrate as an imidazole antifungal with activity against Candida species. The product is administered as a single 5-gram dose containing approximately 100 mg of butoconazole nitrate [1].
Butoconazole is not a biologic and is not subject to biosimilar competition. Competitive products are small-molecule generics and branded or generic vaginal antifungals.
What is the FDA-approved indication?
The approved indication is the local treatment of vulvovaginal candidiasis. The label does not establish butoconazole nitrate as a systemic treatment for invasive candidiasis, recurrent complicated candidiasis or non-vaginal Candida infections [1].
Clinical use is generally directed at uncomplicated vaginal yeast infection. The label warns that patients who do not improve, experience recurrent symptoms or have persistent symptoms may require diagnostic reassessment.
What is the current clinical-trial pipeline for butoconazole nitrate?
Butoconazole nitrate has no visible late-stage clinical development program comparable to a new molecular entity. Its clinical evidence base consists primarily of historical randomized and comparative studies supporting vaginal antifungal efficacy.
Are there active clinical trials?
No major active Phase 2 or Phase 3 program is publicly associated with butoconazole nitrate as of the current public development record. ClinicalTrials.gov searches identify the drug primarily through older treatment studies, observational records or studies of vulvovaginal candidiasis in which several antifungals are evaluated [2].
The absence of a late-stage pipeline reflects the product's established regulatory status rather than a lack of clinical use. Development priorities have shifted toward:
- Short-course and single-dose vaginal therapies.
- Oral azole alternatives.
- Non-azole treatments for resistant Candida.
- Treatments for recurrent vulvovaginal candidiasis.
- Products with improved tolerability, convenience or pregnancy-use profiles.
What did the original clinical studies show?
Historical studies evaluated butoconazole vaginal cream against other imidazole antifungals and multi-day treatment regimens. The clinical objective was symptomatic relief and mycological eradication in patients with vulvovaginal candidiasis.
The single-dose formulation was developed to improve adherence relative to three- or seven-day vaginal regimens. The approved label reports clinical and mycological outcomes from controlled clinical studies supporting the 2% formulation [1].
Modern clinical relevance is constrained by several factors:
- Most studies predate current molecular characterization of Candida species.
- Resistance surveillance was less developed when pivotal studies were conducted.
- Recurrent and non-albicans Candida infections were less central to trial design.
- Contemporary trials increasingly measure recurrence over longer follow-up periods.
What is the market size for butoconazole nitrate?
Public companies do not generally report butoconazole nitrate revenue separately. Market data are usually aggregated into broader categories such as vaginal antifungals, vulvovaginal candidiasis treatments or topical anti-infectives.
Butoconazole is a niche product within the vaginal antifungal market. Its commercial position is smaller than that of:
- Over-the-counter miconazole products.
- Prescription terconazole.
- Oral fluconazole.
- Newer recurrent-infection products such as oteseconazole.
- Newer or alternative non-azole therapies.
Its principal commercial differentiation is the single-dose vaginal regimen. That convenience does not create a durable pricing advantage because generic and alternative products are widely available.
What drives demand for butoconazole nitrate?
Demand is linked to:
- Annual incidence of vulvovaginal candidiasis.
- Preference for local vaginal treatment.
- Prescriber use of single-dose therapy.
- Patient avoidance of oral fluconazole.
- Pregnancy-related treatment considerations, subject to clinician direction.
- Availability and reimbursement of competing products.
- Candida susceptibility and recurrence patterns.
The product's demand is relatively stable but mature. Volume growth is more likely to come from broader diagnosis and treatment of vaginal candidiasis than from premium pricing or major market expansion.
What is the projected market outlook through 2030?
A defensible standalone revenue forecast is difficult because butoconazole nitrate sales are not consistently disclosed by manufacturer or reported as a separate market category. A scenario-based projection is more appropriate than a point estimate.
| Scenario |
2025-2030 unit trend |
Pricing trend |
Market implication |
| Downside |
Decline of 4%-7% annually |
Continued erosion |
Share loss to OTC miconazole, fluconazole and low-cost generics |
| Base case |
Flat to 2% annual growth |
Stable to modest erosion |
Mature niche maintained through single-dose convenience |
| Upside |
3%-5% annual growth |
Limited stabilization |
Supply improvements, renewed prescriber use or broader private-label distribution |
The base case is a mature, low-growth market rather than a high-growth pharmaceutical opportunity. Revenue is likely to remain concentrated among suppliers with reliable manufacturing, pharmacy distribution and payer access.
What could improve the outlook?
The strongest commercial opportunities would involve reformulation or repositioning rather than the existing cream alone. Potential value drivers include:
- Lower-mess vaginal delivery.
- Improved applicator design.
- Reduced leakage.
- Combination treatment for mixed infections.
- Formulations designed for patient populations with adherence challenges.
- Private-label and retail distribution agreements.
- Product positioning for patients who cannot or do not want to use oral azoles.
These opportunities would require new formulation, device or method-of-use evidence. They would not automatically create broad regulatory exclusivity.
What patents protect butoconazole nitrate?
The original composition and formulation patent estate for butoconazole nitrate is mature. Any foundational U.S. patents associated with the original product would have expired or become commercially irrelevant after the product's long market history.
Current competitive protection is more likely to involve:
- Formulation composition.
- Vaginal delivery vehicles.
- Applicator systems.
- Packaging.
- Manufacturing processes.
- Narrow method-of-use claims.
These rights would need to be evaluated claim by claim in the U.S. Patent and Trademark Office database and against current Orange Book listings. The active ingredient itself does not provide a modern patent moat.
What formulation patents could still matter?
A later formulation patent could have commercial relevance if it claims a specific vehicle or delivery system that materially improves:
- Retention in the vaginal tract.
- Drug release.
- Stability.
- Patient tolerability.
- Applicator performance.
- Shelf life.
A formulation patent would generally protect the claimed product configuration, not all butoconazole nitrate products. Generic manufacturers could seek non-infringing formulations or challenge validity.
Are method-of-use patents important?
Method-of-use protection is limited for an established vaginal antifungal. Potential claims could address:
- Treatment of a defined Candida species.
- A specific dosing schedule.
- Use in recurrent infection.
- Treatment in a defined patient subgroup.
- Use with another antifungal or adjunctive therapy.
The practical value of such claims depends on whether the indication is FDA-approved, whether it is listed in the Orange Book and whether generic labeling would induce infringement.
What is the Orange Book status of butoconazole nitrate?
The Orange Book is relevant to approved prescription products and associated patent or exclusivity information. Gynazole-1 is historically associated with an FDA new drug application for butoconazole nitrate vaginal cream.
| Orange Book issue |
Assessment |
| Reference listed drug |
Gynazole-1 or its FDA-recognized reference product history |
| Active ingredient exclusivity |
No meaningful current new-drug exclusivity expected |
| Pediatric exclusivity |
No current commercial significance identified |
| Orphan exclusivity |
Not applicable |
| Patent-based exclusivity |
Foundational protection is mature |
| Generic pathway |
ANDA competition is available where an approved reference and marketable supply exist |
The commercial significance of any listed patent depends on its expiration, delisting status, use codes and the status of corresponding ANDAs. For an old topical product, the principal risk is usually generic price competition rather than a high-value Paragraph IV dispute.
Which companies are challenging butoconazole nitrate exclusivity?
Butoconazole nitrate is not associated with a current high-profile Paragraph IV campaign comparable to recently launched specialty drugs. Generic competition is expected to proceed through routine ANDA pathways, subject to product availability and FDA approval.
Potential competitors include manufacturers of:
- Butoconazole nitrate vaginal cream.
- Miconazole vaginal products.
- Terconazole vaginal cream and suppositories.
- Clotrimazole vaginal products.
- Fluconazole tablets.
- Newer oral or non-azole agents for recurrent infection.
Company-level market shares are difficult to isolate because many generic manufacturers distribute through private-label, contract-manufacturing and wholesaler channels.
Are Paragraph IV challenges a major risk?
Paragraph IV risk is limited in strategic importance because:
- The active ingredient is old.
- Foundational patents are not the principal barrier.
- The product has generic-substitution economics.
- Any remaining protection is more likely to be formulation-specific.
- A challenger would face a modest commercial prize compared with newer branded antifungals.
A Paragraph IV filing could still arise against a surviving formulation patent, but such a case would likely be narrower and more price-sensitive than litigation involving a blockbuster drug.
What patent litigation affects butoconazole nitrate?
No major current U.S. patent litigation has materially altered the commercial outlook for butoconazole nitrate. Historical disputes, if any, would be less relevant than current FDA approvals, supply continuity and reimbursement.
The more important legal questions are:
- Whether a proposed generic uses the same formulation as the reference product.
- Whether an ANDA applicant can certify that no unexpired patent blocks approval.
- Whether any patent claims the cream vehicle or applicator.
- Whether a generic label includes or omits protected uses.
- Whether an Orange Book patent remains enforceable and commercially relevant.
How does butoconazole compare with competing vaginal antifungals?
| Product |
Typical positioning |
Key advantage |
Main commercial pressure |
| Butoconazole nitrate |
Single-dose vaginal cream |
Convenience and local treatment |
Limited differentiation and generic substitution |
| Miconazole |
OTC vaginal treatment |
Broad retail access |
Heavy price competition |
| Terconazole |
Prescription vaginal antifungal |
Established prescription option |
Generic competition |
| Clotrimazole |
OTC or international vaginal treatment |
Low cost and broad availability |
Limited premium potential |
| Fluconazole |
Oral systemic therapy |
Convenience and familiarity |
Drug interactions, contraindications and resistance concerns |
| Oteseconazole |
Recurrent vulvovaginal candidiasis |
Disease-specific prevention strategy |
Higher price and narrower population |
Butoconazole's strongest position is in patients and prescribers who value a one-dose local product. Its weakest position is against low-cost OTC products and oral therapies with strong prescriber familiarity.
What manufacturing and supply barriers exist?
Manufacturing barriers are moderate but not high. The active pharmaceutical ingredient is a mature small molecule, and production does not require biologic fermentation, aseptic filling or complex device engineering.
Operational risks include:
- Consistent micronization and particle-size control.
- Uniform drug distribution in the cream.
- Emulsion stability.
- Applicator filling accuracy.
- Microbial limits and preservative performance.
- Packaging compatibility.
- Scale-up of a semisolid vaginal dosage form.
- FDA process-validation and bioequivalence requirements.
For a generic manufacturer, the larger commercial barrier may be market size. A low-volume product can be unattractive if manufacturing slots, regulatory maintenance and distribution costs exceed expected margin.
What generic launch scenarios exist?
Scenario 1: Continued mature generic supply
Multiple suppliers maintain availability, pricing remains competitive and butoconazole retains a small prescription niche. This is the most likely outcome.
Scenario 2: Supply contraction
One or more manufacturers discontinue the product because of low margins. Temporary shortages could allow remaining suppliers to increase utilization or pricing, but sustained market expansion would remain unlikely.
Scenario 3: Reformulated private-label growth
A manufacturer introduces improved packaging, a more convenient applicator or a retailer-specific presentation. Growth would depend on FDA pathway requirements, retailer adoption and reimbursement.
Scenario 4: Therapeutic displacement
Newer products for recurrent or resistant candidiasis reduce use of conventional vaginal azoles. Butoconazole remains relevant for uncomplicated infections but loses share in higher-value segments.
What is the overall investment and licensing outlook?
Butoconazole nitrate is a low-risk, low-growth generic opportunity. Attractive transactions would be based on manufacturing efficiency, geographic rights, private-label distribution or product-line consolidation rather than on patent exclusivity.
Licensing value could exist for:
- Regional distribution rights.
- Contract manufacturing.
- Authorized generic supply.
- Retail pharmacy or private-label agreements.
- Applicator or delivery-system improvements.
A licensing deal centered only on the old active ingredient would have limited strategic value unless it includes reliable supply, regulatory approvals or differentiated delivery technology.
Key Takeaways
- Butoconazole nitrate is an FDA-approved vaginal imidazole antifungal, primarily marketed as a single-dose 2% cream.
- The product has no meaningful late-stage clinical pipeline.
- Its clinical evidence is mature and based largely on historical controlled studies.
- The market is niche, genericized and highly price-sensitive.
- Foundational patent protection is commercially exhausted; any remaining value would come from formulation, delivery or manufacturing claims.
- Paragraph IV litigation and biosimilar risk are limited.
- Generic availability, supply reliability and distribution are more important than patent strength.
- Through 2030, the most probable outlook is flat to modest decline, with selective growth possible through private-label distribution or delivery improvements.
- The product is better suited to a mature generic or contract-manufacturing strategy than to a branded innovation investment.
Frequently Asked Questions
Is butoconazole nitrate still available in the United States?
Yes. Butoconazole nitrate vaginal cream has FDA-approved product history and may be available through branded, generic or pharmacy-sourced channels, depending on current supplier distribution.
Is butoconazole stronger than miconazole?
Neither product can be ranked as universally stronger. Choice depends on infection history, formulation, tolerability, local resistance patterns, pregnancy considerations and clinician judgment.
Can butoconazole nitrate treat recurrent vulvovaginal candidiasis?
It is approved for vulvovaginal candidiasis, but recurrent disease may require diagnostic confirmation and a longer management strategy. Recurrent infection is a distinct commercial and clinical segment from uncomplicated infection.
Does butoconazole nitrate have biosimilar competition?
No. Butoconazole nitrate is a small-molecule drug, so competition occurs through generic drug applications rather than biosimilar pathways.
Is butoconazole nitrate a high-value patent asset?
No. The active ingredient and original product technology are mature. Any remaining asset value would depend on a specific enforceable formulation, device, manufacturing or method-of-use claim.
References
-
U.S. Food and Drug Administration. (2020). Gynazole-1: Butoconazole nitrate vaginal cream, 2% prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
National Library of Medicine. (2025). ClinicalTrials.gov search results for butoconazole. ClinicalTrials.gov. https://clinicaltrials.gov/search?term=butoconazole
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2025). Drugs@FDA: FDA-approved drugs database. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., Zaoutis, T. E., & Sobel, J. D. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62(4), e1-e50. https://doi.org/10.1093/cid/civ933
